Exact Sciences' 2024 sales grew 10% to $2.76 billion, exceeding estimates. New cancer tests, including Cologuard Plus, are ...

They’re non-invasive with none of the dreaded prep. But are recently approved home tests for colon cancer as effective as ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.CDDzvsGh.js ...

Reports preliminary FY24 revenue $2.76B, consensus $2.74B. Plans to launch three new cancer tests in 2025, namely Cologuard Plus, ...

EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection ...

Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael ...

The report also indicates that while PAMA has cut spending on routine tests, overall lab spending has risen as genetic testing continues to grow.

Munn credited the risk assessment test, which uses various factors to evaluate lifetime breast cancer risk, for her early diagnosis. After hearing Munn's story, Hall decided to take the same test.

ORACLE test predicts overall cancer survival independent of currently used clinical risk factors, and it has the best predictive power in stage 1 lung cancer. A high ORACLE score is associated with a ...